Favorable Outcomes with New Generation Transcatheter Heart Valves in Bicuspids

Original Title: Bicuspid Aortic Valve Stenosis Favorable Early Outcomes UIT a Next-Generation Transcatheter Heart Valve in a Multicenter Study. Reference: Gidon Y. Perlman J Am Coll Cardiol Interv 2016;9:817-24

Courtesy of Dr. Carlos Fava.

Congenital bicuspid aortic valves are infrequent and are associated with severe calcification in elderly patients.

Transcatheter aortic valve replacement to treat bicuspid aortic stenosis is challenging because of their anatomical characteristics and there is not enough evidence on its outcomes.

This study included 51 patients with bicuspid aortic valves receiving an Edwards SAPIENS 3.

Mean patient age was 76 and little more than half were women with STS score 5.2±3.7%.

The procedure was done in 20 patients under sedation and local anesthetics, two via carotid access and the rest via femoral.

There were no deaths, malposition, embolization, second valves or conversion to surgery.

At 30 days, the gradient decreased from 49.4±16 mmHg at baseline to 11.2±4.7 mmHg, and the area increased from 0.7±0.2 cm2 to 1.7±0.3 cm2. There was none/trivial aortic regurgitation in 32 patients and none presented moderate or severe regurgitation.

During the first month, there were 2 deaths, 2 major vascular complications and 12 patients required a definite pacemaker.

The need for a definite pacemaker was associated with implantation >8 mm below annulus level (low implantation, 55% need for pacemaker vs. 10% higher implantation; p=0.01).

Conclusion
TAVI in bicuspid valves with new generation devices was feasible and effective with a favorable performance and no cases of moderate or severe aortic regurgitation.

Editorial Comment
Bicuspid valves are different in morphology, are more calcified and are associated with moderate and severe aortic regurgitation.

New generation valves improve performance and encourage us to advance with this group, improving accuracy of position implantation position in order to avoid pacemaker implantation after TAVI.
Courtesy of Dr. Carlos Fava.
Interventional Cardiologist
Favaloro Foundation – Buenos Aires

More articles by this author

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

Coronary revascularization before TAVI: prior PCI or conservative management?

The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

Percutaneous Mechanical Aspiration versus Surgical Treatment of Tricuspid Valve Endocarditis

Tricuspid valve infective endocarditis (TVIE) accounts for approximately 5% to 10% of all cases of infective endocarditis. Surgical treatment remains the standard therapy in...

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

ACC 2026 | FAST III: vFFR vs FFR in physiology-guided revascularization of intermediate coronary lesions

Physiological assessment of intermediate coronary lesions remains a cornerstone in decision-making for coronary revascularization. Although FFR continues to be one of the guideline-recommended references,...